SCHEMBL250447

SCHEMBL250447

CCCCNc1c(OC)ccc2nc3ccccc3cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.50
POLB P06746 2/20 0.49
RAD52 P43351 2/20 0.49
KDM4E B2RXH2 1/20 0.49
TTR P02766 1/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
ACHE P22303 11/20 0.47
BCHE P06276 8/20 0.47
CACNA2D1 P54289 1/20 0.45
SLC2A1 P11166 4/20 0.45
KMT2A Q03164 2/20 0.45
NPC1 O15118 1/20 0.45
APOBEC3A P31941 1/20 0.45
RAB9A P51151 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45
MEN1 O00255 1/20 0.44
CHEK2 O96017 1/20 0.44
FLT1 P17948 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30770846 1.00 TLR8 (0.50) TLR8POLBRAD52KDM4ETTR
Ammonia Solution, Strong SCHEMBL2531927 0.99 TLR8 (0.49) TLR8POLBRAD52KDM4ETTR
SCHEMBL10424918 0.76 SLC2A1 (0.46) TLR8POLBRAD52KDM4EACHE
SCHEMBL9748474 0.75 POLB (0.70) POLBRAD52KDM4ETTRGLA
SCHEMBL28465683 0.73 TLR8 (0.44) TLR8POLBRAD52KDM4ETTR
SCHEMBL9755341 0.72 POLB (0.55) TLR8POLBRAD52KDM4EGLA
SCHEMBL5393759 0.72 TLR8 (0.59) TLR8POLBRAD52KDM4EGLA
SCHEMBL27512057 0.71 TLR8 (0.58) TLR8KDM4EGAAMAPTCACNA2D1
SCHEMBL27459127 0.71 TLR8 (0.58) TLR8KDM4EGAAMAPTCACNA2D1
SCHEMBL8418578 0.71 TLR8 (0.50) TLR8POLBRAD52KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637492-B2 Peptide inhibitors of focal adhesion kinase activity and uses thereof ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2026-05-26 US disclosed
US-12521386-B2 Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2026-01-13 US disclosed
US-12509468-B2 Quindoline compounds and uses thereof ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2025-12-30 US disclosed
US-20250276953-A1 SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-09-04 US disclosed
US-20250189527-A1 COMPOSITIONS AND METHODS FOR DETECTING, PREDICTING RISK OF DEVELOPING, AND TREATING LEPTOMENINGEAL DISEASE DUKE UNIVERSITY 2025-06-12 US disclosed
EP-4427812-A2 SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE The Regents of the University of Michigan (US) 2024-09-11 EP disclosed
EP-3934634-B1 SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE UNIV MICHIGAN REGENTS (US) 2024-07-24 EP disclosed
US-20240239764-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-07-18 US disclosed
US-20240150452-A1 MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF CATALENT PHARMA SOLUTIONS, LLC 2024-05-09 US disclosed
US-11944626-B2 Small molecule inhibitors of ALDH and uses thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-04-02 US disclosed
US-20120035244-A1 PARP1 TARGETED THERAPY THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-02-09 US disclosed
US-8088931-B2 Small molecule inhibitors of MDM2 and the uses thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-01-03 US disclosed
US-20110251216-A1 COMPOSITIONS AND METHODS FOR INHIBITING EZH2 THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-10-13 US disclosed
WO-2011102999-A2 SPINK1 TARGETED THERAPY THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-08-25 WO disclosed
US-20110135710-A1 Methods and Compositions for the Inhibition of Gene Expression PRONAI THERAPEUTICS, INC. (US) 2011-06-09 US disclosed
US-7932382-B2 Amide substituted heterocylic compound; anticarcinogen; inducing apoptotic cell death, sensitizing cells to inducers of apoptosis THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-04-26 US disclosed
US-20110092452-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PANCREATIC CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-04-21 US disclosed
US-7910621-B2 Small molecule antagonists of XIAP family proteins THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-03-22 US disclosed
US-20110020434-A1 NANOPARTICLE ARSENIC-PLATINUM COMPOSITIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-01-27 US disclosed
US-20090118377-A1 APOGOSSYPOLONE AND THE USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150452-A1 MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF CD2BP2, DSTN, SDCBP TLR8 2523/4885POLB 3888/4885RAD52 1967/4885
US-20240239764-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS EGFR, ERBB2, ERBB3 TLR8 4418/4885POLB 521/4885RAD52 2591/4885
US-12509468-B2 Quindoline compounds and uses thereof TPD52L2, BRDT, RECQL TLR8 3504/4885POLB 779/4885RAD52 583/4885
US-20090118377-A1 APOGOSSYPOLONE AND THE USES THEREOF BCL2, BAD, BAX TLR8 4045/4885POLB 3072/4885RAD52 2755/4885
US-20110251216-A1 COMPOSITIONS AND METHODS FOR INHIBITING EZH2 EZH2, BMI1, EZH1 TLR8 4305/4885POLB 1196/4885RAD52 2057/4885
US-11944626-B2 Small molecule inhibitors of ALDH and uses thereof ALDH2, ALDH1A1, ALDH3A1 TLR8 4838/4885POLB 2089/4885RAD52 1409/4885
US-20120035244-A1 PARP1 TARGETED THERAPY PARP1, PARP11, PARP12 TLR8 4011/4885POLB 28/4885RAD52 106/4885
US-20250276953-A1 SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF SIRT6, SIRT2, SIRT1 TLR8 2294/4885POLB 3692/4885RAD52 394/4885
US-12637492-B2 Peptide inhibitors of focal adhesion kinase activity and uses thereof PTK2, ILK, FPR2 TLR8 177/4885POLB 4417/4885RAD52 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.